San Diego, CA — January 9, 2026 — Leads & Copy — iBio, Inc. (NASDAQ:IBIO) announced it has entered a securities purchase agreement with healthcare-focused institutional investors for a private placement expected to yield approximately $26 million before fees and expenses.
The offering is expected to close around January 13, 2026, pending standard closing conditions.
Frazier Life Sciences led the financing, with participation from existing investors.
iBio plans to use the net proceeds to advance its preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs. Funds will also support other preclinical pipeline assets and general corporate purposes, extending iBio’s cash runway into 2028.
The company will sell 11,061,738 shares of common stock (or pre-funded warrants) at $2.35 per share (or $2.349 per warrant), subject to beneficial ownership limitations.
Leerink Partners was the lead placement agent for the offering, with LifeSci Capital and Oppenheimer & Co. as co-placement agents.
The unregistered shares and pre-funded warrants were offered under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. These securities have not been registered with the SEC or under state securities laws and may not be offered or sold in the United States without registration or an applicable exemption. The securities were offered only to accredited investors, and the Company agreed to file one or more registration statements with the SEC covering the resale of the unregistered shares of common stock and the shares issuable upon exercise of the unregistered pre-funded warrants.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any jurisdiction where such offer, solicitation, or sale would be unlawful before registration or qualification under securities laws.
iBio (Nasdaq: IBIO) is leveraging AI and computational biology to develop biopharmaceuticals for cardiometabolic diseases, obesity, cancer, and other diseases. The company combines 3D modeling with drug discovery platforms to create antibody treatments.
Any statements regarding future expectations, plans, and prospects, and any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the intended use of proceeds, the expected gross proceeds from the offering, and the expected extension of the Company’s cash runway into calendar 2028. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2025, and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Investor Relations can be contacted at ir@ibioinc.com.
Ignacio Guerrero-Ros, Ph.D., or David Schull of Russo Partners, LLC can be reached at Ignacio.guerrero-ros@russopartnersllc.com or David.schull@russopartnersllc.com or (858) 717-2310 or (646) 942-5604.
Source: iBio, Inc.
